The stock of POINT Biopharma Global Inc. (NASDAQ:PNT) decreased by -$0.06 on Friday to finish at $8.99, down -0.66 percent. The last five days have seen an average of 524,840 shares of common stock traded. 14 times new highs were reached in the current year, with a gain of $1.70. The average number of shares traded over the last 20 days was 547,535, while the average volume over the last 50 days totaled 648,120.
PNT stock dropped -3.02% since last month. On 08/09/23, the company’s shares reached a one-month low of $8.28. The stock touched a high of $11.13 on 05/15/23, after rallying from a low of $5.59 in 52 weeks. The price of PNT stock has risen by 23.32% or $1.70 this year, reaching a new high 14 times. Still, the stock price is down -19.23% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
PNT stock investors should be aware that POINT Biopharma Global Inc. (PNT) stock had its last reported insider trading activity 258 days ago on Nov 29. On Nov 29, Chief Executive Officer MCCANN JOE A. acquired 2,160 shares at $6.64 each. This transaction resulted in the insider spending $14,342. On Nov 28, Malik Rajesh added 3,700 shares at a price of US$6.66. After the transaction, the insider now owns 3,700 shares. Director HOGUE GERALD L. had earlier bought 3,660 shares on Nov 25 for $6.82 a share. The transaction was completed for $24,943.
Valuation Metrics
POINT Biopharma Global Inc. (PNT) has a trailing price-to-earnings (P/E) ratio of 11.59. Beta for the stock is 0.10. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 4.05, the price-to-book (PB) ratio of 2.01, and the price-to-cash flow ratio of 6.12.
Financial Health
For the three months ended March 30, POINT Biopharma Global Inc.’s quick ratio was 5.60, while its current ratio was 5.60, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $101.06 million and revenue of $226.58 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PNT’s return on assets (ROA) during the last 12 months has been 23.10%. There was a 19.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 26.50%.
Earnings Surprise
According to POINT Biopharma Global Inc.’s quarterly financial report for the quarter that ended March 30, it had $318.89 million in cash and short-term investments. Net income for the quarter came in at $9.46 million, while revenues rose by 100.0% to $226.58 million. It was predicted that POINT Biopharma Global Inc.’s quarterly earnings would be -$0.16, but it ended up being -$0.31, beating the consensus by 48.40%. EBITDA was -$25.09 million for the quarter. Equity owned by shareholders amounts to $105.69 million.
Technical Picture
Here’s a quick look at POINT Biopharma Global Inc.’s (PNT) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 53.10%, suggesting the stock is Neutral, with a 53.36% historical volatility rate.
The stochastic %K and %D were 50.73% and 32.13% respectively, while the average true range (ATR) was 0.38. Based on the 14-day stochastic reading of 68.78%, the RSI (14) reading is 50.12%. On the 9-day MACD Oscillator, the stock is at 0.04, and the 14-day reading is at -0.03.
Analyst Ratings
Analysts have assigned POINT Biopharma Global Inc. (PNT) an Buy rating. PNT is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 11 others recommend it as a buy.
What is PNT’s price target for the next 12 months?
The current consensus forecast for the stock is between $13.00 and $28.00, with a median target price of $15.00. In analyzing these forecasts, the average price target given by analysts for POINT Biopharma Global Inc. (PNT) is $17.00.
